Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors
Authors
Boni, VGarcia-Corbacho, J
Ott, PA
Cho, DC
Autio, KA
Uboha, N
Spira, AI
Humphrey, R
Will, M
Naing, A
Thistlethwaite, Fiona C
de Vries, EGE
Arkenau, HT
Affiliation
Medical Oncology, START Madrid-CIOCC HM Hospital Sanchinarro, Madrid, SpainIssue Date
2018
Metadata
Show full item recordCitation
Boni V, Garcia-Corbacho J, Ott PA, Cho DC, Autio KA, Uboha N, et al. 435P Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors. Annals of Oncology. 2018;29(suppl_8).Journal
Annals of OncologyDOI
10.1093/annonc/mdy279.422PubMed ID
No PMIDAdditional Links
https://dx.doi.org/10.1093/annonc/mdy279.422Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy279.422